Market Cap (In USD)
231.92 Thousand
Revenue (In USD)
-
Net Income (In USD)
-5.9 Million
Avg. Volume
-
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.0113-0.0154
- PE
- -
- EPS
- -
- Beta Value
- 0.249
- ISIN
- US87807D1110
- CUSIP
- 87807D111
- CIK
- 1872812
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Bryan Leland Kobel
- Employee Count
- -
- Website
- https://www.tcbiopharm.com
- Ipo Date
- Details
- TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
More Stocks
-
080580Okins Electronics Co., Ltd.
080580
-
WWNTF
-
BALMLAWRIEBalmer Lawrie & Co. Ltd.
BALMLAWRIE
-
5536
-
RTMNF
-
688608
-
603309Well Lead Medical Co., Ltd.
603309
-
000977